{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/back-pain-low-without-radiculopathy/how-up-to-date-is-this-topic/update/","result":{"pageContext":{"chapter":{"id":"98f67efe-dc7d-5678-ad87-be8f6369b281","slug":"update","fullItemName":"Update","depth":2,"htmlHeader":"<!-- begin field 5cad137e-00f2-405f-924d-78a9b96efd8e --><h2>Update</h2><!-- end field 5cad137e-00f2-405f-924d-78a9b96efd8e -->","summary":null,"htmlStringContent":"<!-- begin item ccfc6e75-58e9-420a-9571-dceae300ef0b --><!-- end item ccfc6e75-58e9-420a-9571-dceae300ef0b -->","topic":{"id":"67ec8276-483f-5bd3-a1d4-abc190687cec","topicId":"9b18de7f-5dbf-47fa-b614-8130c5721d6c","topicName":"Back pain - low (without radiculopathy)","slug":"back-pain-low-without-radiculopathy","lastRevised":"Last revised in November 2020","chapters":[{"id":"d8279135-bdfb-5f8d-a638-9f5c15e8e31e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"94f53f0f-68b9-57d2-bb9b-9205b4128d2a","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"1e14b540-8ee6-5ec6-a360-b55991b947f3","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"6ce99d9d-152d-5b24-87b1-279f7cca5449","slug":"changes","fullItemName":"Changes"},{"id":"98f67efe-dc7d-5678-ad87-be8f6369b281","slug":"update","fullItemName":"Update"}]},{"id":"4fa9a83d-808c-53a6-95a7-4906ba0762b3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"3b4be10b-9039-5c16-9f5c-e53279f4ef3a","slug":"goals","fullItemName":"Goals"},{"id":"ac362b69-f985-5883-8d14-7b25b4cd4c92","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"1581e495-09a8-5389-a60c-1a3b417b8be7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5ffd119a-f7fe-5e5d-9891-d3e921d92d40","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b051c066-56d4-5c85-8b28-98014a97b749","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"302a3eb3-4a2b-550a-89a6-cd26e0eef14a","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"bd777de4-3ef6-529d-bcbf-8bf6aa892e99","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"2e9191b9-9306-5480-be62-c1f812b84b32","slug":"definition","fullItemName":"Definition"},{"id":"810863bb-72c6-58eb-bb75-3e2f1ee214b2","slug":"prevalence","fullItemName":"Prevalence"},{"id":"b2234c07-e852-5713-8078-e978d40b2b82","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"16569068-7bdd-5aad-b47c-7e935d6c6254","slug":"prognosis","fullItemName":"Prognosis"},{"id":"a40462ae-8085-5573-a267-170ee6539bbb","slug":"complications","fullItemName":"Complications"}]},{"id":"140fe6e6-d5e6-56f6-a4ac-d1791b9a1de1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"6540e013-bdca-57be-8415-3dacd0fd448a","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"b2bb39a7-3f14-593c-a0bb-11b6229e9193","slug":"red-flag-symptoms-signs","fullItemName":"Red flag symptoms and signs"}]},{"id":"41781ac6-3970-5128-9f67-8103d95876c0","fullItemName":"Management","slug":"management","subChapters":[{"id":"1d96563b-1a08-575c-a108-6e566028123f","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"18c68aea-1807-5bbb-a514-d9f773a881fb","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"53da469c-6c3c-5af5-b251-e252f8f3ae47","slug":"diazepam","fullItemName":"Diazepam"},{"id":"e815c8fc-c6d6-5168-aacd-92b8545caf45","slug":"nonsteroidal-anti-inflammatory-drugs","fullItemName":"Nonsteroidal anti-inflammatory drugs"},{"id":"9aaa155a-4c14-58c4-a24d-a0d7594586c1","slug":"paracetamol","fullItemName":"Paracetamol"},{"id":"f098cbb6-72ba-503d-b622-a02915fe6668","slug":"weak-opioids","fullItemName":"Weak opioids"}]},{"id":"9607837f-245f-5649-86a7-425a90fe7c11","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"c264a034-a901-521f-83d9-6e19cfe6295a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"12ec6fad-43c6-5117-b906-d169335441b2","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"d262f13b-ed13-541d-9ca8-e7075aebd557","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"089c38f6-7158-5d2f-9683-e1e16a2e7bc9","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"62a8100d-ffe9-5e3b-8ca4-071a242c2406","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6dbc5aaa-df51-510a-af88-268983a5b382","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"81117569-d1c8-597d-a361-fa9822c7a4f7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1e14b540-8ee6-5ec6-a360-b55991b947f3","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"c317a0e0-c224-55ba-b5c4-6c15c407d11c","slug":"new-evidence","fullItemName":"New evidence","depth":3,"htmlHeader":"<!-- begin field 1909d0a6-24f0-499d-8c78-b2edabbbf9aa --><h3>New evidence</h3><!-- end field 1909d0a6-24f0-499d-8c78-b2edabbbf9aa -->","summary":null,"htmlStringContent":"<!-- begin item c872d9db-aee0-4450-80d1-9dcc097a5adc --><!-- begin field 7b06cfce-da96-4295-8f76-6a3e0924374c --><h3>Evidence-based guidelines</h3><!-- end field 7b06cfce-da96-4295-8f76-6a3e0924374c --><!-- begin field 5d580ea4-5473-401b-beee-263a5b8ed064 --><ul><li>Hartvigsen, J., Hancock, M. J., Kongsted, A., et al. (2018) What low back pain is and why we need to pay attention. The Lancet. [<a href=\"http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)30480-X/fulltext\" data-hyperlink-id=\"baa01b6a-2220-4a22-97a8-a931009d2341\">Free Full-Text</a>]</li></ul><!-- end field 5d580ea4-5473-401b-beee-263a5b8ed064 --><!-- begin field 771c28a4-17c3-42a8-a404-e37d067f32a7 --><h3>HTAs (Health Technology Assessments)</h3><!-- end field 771c28a4-17c3-42a8-a404-e37d067f32a7 --><!-- begin field ab79b648-7fdd-43d3-9a80-ac126fe65a15 --><p>No new HTAs since 1 January 2017.</p><!-- end field ab79b648-7fdd-43d3-9a80-ac126fe65a15 --><!-- begin field 3f7def69-827f-4b81-8a71-fa5381dfee5b --><h3>Economic appraisals</h3><!-- end field 3f7def69-827f-4b81-8a71-fa5381dfee5b --><!-- begin field f36bd535-7811-4c4a-b0ce-5e63c911230f --><p>No new economic appraisals relevant to England since 1 January 2017.</p><!-- end field f36bd535-7811-4c4a-b0ce-5e63c911230f --><!-- begin field 9163a7bf-9ae8-471e-a067-b09ba1dc0a9e --><h3>Systematic reviews and meta-analyses</h3><!-- end field 9163a7bf-9ae8-471e-a067-b09ba1dc0a9e --><!-- begin field 41a3e2f9-ead6-46d0-a6d7-b93ba4621c72 --><ul><li>NIHR (2018) <em>Opioid drugs are no better than standard painkillers for long-term back and joint pain. </em>National Institute for Health Research. <a href=\"https://www.nihr.ac.uk/\" data-hyperlink-id=\"5808db9a-213f-43ae-b107-a91500d265f9\">www.nihr.ac.uk</a> [<a href=\"https://discover.dc.nihr.ac.uk/content/signal-000610/opioid-drugs-are-no-better-than-standard-painkillers-for-long-term-back-and-joint-pain\" data-hyperlink-id=\"031c9835-a765-431c-868a-a91500d26738\">Free Full-text</a>]</li><li>van der Gaag, W.H., Roelofs, P.D.D.M., Enthoven W.T.M. et al (2020) Non-steroidal anti-inflammatory drugs for acute low back pain. Cochrane Systematic Review. <a href=\"https://www.cochranelibrary.com/\" data-hyperlink-id=\"ef18b2ac-1ea8-43ca-b5ae-aba000a0fda4\">www.cochranelibrary.com</a> [<a href=\"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013581/full\" data-hyperlink-id=\"46f9b740-dd15-446c-a224-aba000a0feac\">Free Full-text</a>]</li></ul><!-- end field 41a3e2f9-ead6-46d0-a6d7-b93ba4621c72 --><!-- begin field d10c4df1-200e-4863-8e66-86d5a4c9a5c2 --><h3>Primary evidence</h3><!-- end field d10c4df1-200e-4863-8e66-86d5a4c9a5c2 --><!-- begin field 7fcf7068-aaf0-4f6e-bffc-5e5650ee75af --><p>No new randomized controlled trials published in major journals since 1 January 2017.</p><!-- end field 7fcf7068-aaf0-4f6e-bffc-5e5650ee75af --><!-- end item c872d9db-aee0-4450-80d1-9dcc097a5adc -->","subChapters":[]},{"id":"6a9d5fce-ac09-552c-9db4-25580b80a300","slug":"new-policies","fullItemName":"New policies","depth":3,"htmlHeader":"<!-- begin field 13d014ad-5c8f-4339-9dfa-3dd2daff6849 --><h3>New policies</h3><!-- end field 13d014ad-5c8f-4339-9dfa-3dd2daff6849 -->","summary":null,"htmlStringContent":"<!-- begin item fb0a2be2-20e7-4cd1-9219-c1da7f6b0eef --><!-- begin field 0ed9e13c-112d-4cd1-8b6d-62ec90422ee5 --><p>No new national policies or guidelines since 1 January 2017.</p><!-- end field 0ed9e13c-112d-4cd1-8b6d-62ec90422ee5 --><!-- end item fb0a2be2-20e7-4cd1-9219-c1da7f6b0eef -->","subChapters":[]},{"id":"ebe38fe4-7a47-5354-8767-49385bcf3cfb","slug":"new-safety-alerts","fullItemName":"New safety alerts","depth":3,"htmlHeader":"<!-- begin field da0d6cac-63c0-49ef-9a1c-fd5e1cf636e2 --><h3>New safety alerts</h3><!-- end field da0d6cac-63c0-49ef-9a1c-fd5e1cf636e2 -->","summary":null,"htmlStringContent":"<!-- begin item d04d996c-db60-40fc-acf4-49973da5cbea --><!-- begin field 067f2e12-003f-42c6-9f37-84673d787370 --><p>No new safety alerts since 1 January 2017.</p><!-- end field 067f2e12-003f-42c6-9f37-84673d787370 --><!-- end item d04d996c-db60-40fc-acf4-49973da5cbea -->","subChapters":[]},{"id":"a8855ef8-6327-5268-86b8-f7c66c8e5e5e","slug":"changes-in-product-availability","fullItemName":"Changes in product availability","depth":3,"htmlHeader":"<!-- begin field dfb8bfff-cd2b-48cb-ab78-3228f036cac2 --><h3>Changes in product availability</h3><!-- end field dfb8bfff-cd2b-48cb-ab78-3228f036cac2 -->","summary":null,"htmlStringContent":"<!-- begin item 27f168f4-c164-4fa2-ab75-464d5ab04272 --><!-- begin field 03040739-8a4d-47c0-8135-3adc2864a593 --><div class=\"app-container prod has-role-admin has-role-author has-role-beta has-role-reviewer has-role-technicalauthor has-role-user\" style=\"height: 969px;\"><div class=\"outer-page-container\" style=\"margin: 0px 15px; height: 872.094px;\"><div class=\"authoring-content-container\" style=\"display: flex; flex-direction: column; height: 872.094px;\"><div class=\"main-authoring-content-pane\" style=\"height: 808.094px;\"><div class=\"authoring-sidenav-content ng-star-inserted\" style=\"display: flex; height: 808.094px; justify-content: left;\"><div><ul><li>Pridinol (Myopridin) is licensed for central and peripheral muscle spasms including lumbar pain, torticollis, and general muscle pain. It acts on alpha motor neurones in the spine to relieve skeletal muscle tension of both central and peripheral origin. See more <a href=\"https://www.mims.co.uk/new-muscle-spasm-treatment-option/musculoskeletal-disorders/article/1704164\" target=\"_blank\" rel=\"noopener\" data-hyperlink-id=\"181f4fd7-5619-42ce-a54b-acb400cfa772\">here</a>.</li></ul></div><div id=\"tooltip-details-pane\" class=\"tooltip-details-container\" style=\"display: block; color: #414141; background: #f1f1f1; border: 1px solid #a9a9a9; position: absolute; z-index: 1300; width: 450px; padding: 6px 8px; box-shadow: rgba(0, 0, 0, 0.4) 1px 3px 3px; transition: opacity 300ms linear 0s, visibility 300ms linear 0s; visibility: hidden; top: 0px; left: 0px;\"><span class=\"tooltip-details-pane-buttons\"><button class=\"show-ref-sheet\" style=\"border-radius: 50%; background-color: ivory; border: none; padding: 2px; line-height: 0.5; margin-left: 5px; cursor: pointer; outline: none; font-size: 1em; color: black;\" aria-describedby=\"cdk-describedby-message-700\"></button></span><h3 class=\"title\" style=\"display: block; margin-inline: 0px; font-weight: bold; font-size: 1.2em; margin-block: 1em; font-style: italic; font-variant: small-caps; line-height: 1em; margin-bottom: 2px; margin-top: 0px;\"> </h3><p class=\"desc\" style=\"font-size: 1em; margin-bottom: 6px;\"> </p></div></div></div></div></div></div><!-- end field 03040739-8a4d-47c0-8135-3adc2864a593 --><!-- end item 27f168f4-c164-4fa2-ab75-464d5ab04272 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}